Received: 4 October 2021
Accepted: 5 April 2022
First Online: 6 May 2022
: This study protocol was reviewed and approved by the independent ethics committee or institutional review board (Comitato Etico Indipendente del Policlinico Sant’Orsola-Malpighi Padiglione 3, Via Albertoni, 15, Bologna 40138). The study was conducted according to the ethical principles described in the Declaration of Helsinki. All participants gave signed informed consent to participate.
: Not applicable.
: MAP, PS, AKLR, DS, and HG had nothing to disclose. MCH reported personal fees and expert testimony from Novartis; grants and personal fees from Deciphera Pharmaceuticals and Blueprint Medicines; personal fees and equity interest from Molecular MD, outside the submitted work. In addition, MCH also reported a patent ‘Treatment of Gastrointestinal Stromal Tumors’ with royalties paid and partial salary support from a Veterans Affairs Merit Review Grant (I01 BX000338). AI reported grants and personal fees from Bayer; grants from Merck, MSD, Novartis, Chugai, and Astra Zeneca; and personal fees from Springworks, outside the submitted work. CV reported personal fees, advisory board, and travel expenses from Bayer, Pfizer, PharmaMar, and Lilly; and advisory board from Mundipharma and GSK, outside the submitted work. GG reported grants and personal fees from Novartis, Bayer, and PharmaMar; personal fees from Pfizer, Merck, EISAI, and Lilly; and travel support from Tesaro, outside the submitted work. SB reported grant from Incyte, Blueprint Medicines, and Novartis; personal fees from Deciphera, Blueprint Medicines, Lilly, Novartis, Daichii-Sankyo, Plexxikon, Exelixis, and Bayer; and CME from Pfizer, during the conduct of the study. In addition, SB also reported personal fees from PharmaMar, Lilly, Roche, and GSK, outside the submitted work. PR reported personal fees from Bayer, Clinigen, BMS, Roche, MSD, Deciphera, Novartis, Pfizer, PharmaMar, Lilly, and Amgen, outside the submitted work. GB, UB, and TS are Novartis employees. The authors declare no conflict of interest regarding the content discussed in the manuscript.